Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Janno, S. Articles by Wahlbeck, K. Search for Related Content PubMed Citation Articles by Janno, S. Articles by Wahlbeck, K. Schizophrenia Spectrum Disorders Symptoms/Dimensions Other Neuroleptics

Prevalence of Neuroleptic-Induced Movement Disorders in Chronic Schizophrenia Inpatients

OBJECTIVE: Since most of the world’s schizophrenia patients are treated with conventional antipsychotics, the authors evaluated various methods for establishing the prevalence of neuroleptic-induced movement disorders in these patients. METHOD: DSM-IV criteria and established score thresholds on a movement disorder rating scale were used to identify cases of neuroleptic-induced movement disorder in a representative Estonian patient sample of 99 chronic institutionalized schizophrenia patients, 18–65 years old, treated with conventional neuroleptics (79.8%) or clozapine (20.2%). RESULTS: Neuroleptic-induced movement disorders according to DSM-IV criteria were found in 61.6% of the group: 31.3% had neuroleptic-induced akathisia, 23.2% had neuroleptic-induced parkinsonism, and 32.3% had neuroleptic-induced tardive dyskinesia. Prevalence rates for akathisia and tardive dyskinesia were similar when either DSM-IV criteria or rating scale scores were used, but the prevalence rate for parkinsonism was much lower per DSM-IV criteria than according to rating scale score. CONCLUSIONS: Nearly two-thirds of chronic schizophrenia patients suffered from a neuroleptic-induced movement disorder. Globally, extrapyramidal adverse effects still impose a huge burden on the majority of neuroleptic-treated individuals with schizophrenia. The discrepancy between the standard identification methods for neuroleptic-induced movement disorder indicate the need for further research.

This article has been cited by other articles:

				R. Hieber, T. Dellenbaugh, and L. A. Nelson Role of Mirtazapine in the Treatment of Antipsychotic-Induced Akathisia Ann. Pharmacother., June 1, 2008; 42(6): 841 - 846. [Abstract] [Full Text] [PDF]

				K. L. Claxton, J. J. Chen, and D. M. Swope Drug-Induced Movement Disorders Journal of Pharmacy Practice, December 1, 2007; 20(6): 415 - 429. [Abstract] [PDF]

				I. Back and M. Taubert A case report : Akathisia and an unusual symptomatic treatment Palliative Medicine, December 1, 2007; 21(8): 713 - 715. [Abstract] [PDF]

				Other articles noted Evid. Based Ment. Health, August 1, 2004; 7(3): 67 - 68. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2004 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us